JP2006520397A5 - - Google Patents

Download PDF

Info

Publication number
JP2006520397A5
JP2006520397A5 JP2006507956A JP2006507956A JP2006520397A5 JP 2006520397 A5 JP2006520397 A5 JP 2006520397A5 JP 2006507956 A JP2006507956 A JP 2006507956A JP 2006507956 A JP2006507956 A JP 2006507956A JP 2006520397 A5 JP2006520397 A5 JP 2006520397A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
heterocycle
nhc
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520397A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2004/000351 external-priority patent/WO2004081008A1/en
Publication of JP2006520397A publication Critical patent/JP2006520397A/ja
Publication of JP2006520397A5 publication Critical patent/JP2006520397A5/ja
Pending legal-status Critical Current

Links

JP2006507956A 2003-03-14 2004-03-10 新規融合トリアゾロン類及びその使用 Pending JP2006520397A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45507303P 2003-03-14 2003-03-14
US46769003P 2003-05-02 2003-05-02
US53634304P 2004-01-14 2004-01-14
PCT/SE2004/000351 WO2004081008A1 (en) 2003-03-14 2004-03-10 Novel fused triazolones and the uses thereof

Publications (2)

Publication Number Publication Date
JP2006520397A JP2006520397A (ja) 2006-09-07
JP2006520397A5 true JP2006520397A5 (enExample) 2007-05-10

Family

ID=32995996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006507956A Pending JP2006520397A (ja) 2003-03-14 2004-03-10 新規融合トリアゾロン類及びその使用

Country Status (10)

Country Link
US (1) US20070149560A1 (enExample)
EP (1) EP1613625A1 (enExample)
JP (1) JP2006520397A (enExample)
KR (1) KR20050119647A (enExample)
AU (1) AU2004220176A1 (enExample)
BR (1) BRPI0408256A (enExample)
CA (1) CA2519107A1 (enExample)
MX (1) MXPA05009885A (enExample)
NO (1) NO20054083L (enExample)
WO (1) WO2004081008A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
JPWO2005063222A1 (ja) 2003-12-26 2007-07-19 協和醗酵工業株式会社 Hsp90ファミリー蛋白質阻害剤
AU2006214247C1 (en) 2005-02-16 2012-11-08 Anacor Pharmaceuticals, Llc Boron-containing small molecules
NZ556718A (en) * 2005-02-18 2010-10-29 Astrazeneca Ab Method for determining responsiveness to CHKI inhibitors
KR20080074963A (ko) * 2005-11-10 2008-08-13 쉐링 코포레이션 단백질 키나제 억제제로서의 이미다조피라진
BRPI0621279B1 (pt) 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
CN102532180B (zh) * 2005-12-30 2016-06-29 安纳考尔医药公司 含硼的小分子
EP1978966A4 (en) * 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US8012965B2 (en) 2006-12-29 2011-09-06 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2009002955A1 (en) * 2007-06-27 2008-12-31 Sanofi-Aventis U.S. Llc Process for the preparation of (2r)-2-[4-(7-bromo-2-quinolyloxy)phenoxy]propanoic acid
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
WO2010004319A1 (en) * 2008-07-07 2010-01-14 Astrazeneca Ab Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt
CA2749843C (en) 2009-01-16 2017-09-05 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US8614221B2 (en) 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
JP2013518886A (ja) 2010-02-03 2013-05-23 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼ阻害剤
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
CN104884449A (zh) 2012-10-31 2015-09-02 拜尔农作物科学股份公司 作为害虫防治剂的新的杂环化合物
KR102164612B1 (ko) * 2014-04-24 2020-10-12 동아에스티 주식회사 아졸계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
TW202342477A (zh) 2022-03-01 2023-11-01 香港商英矽智能科技知識產權有限公司 二醯基甘油激酶(DGK) α抑制劑及其用途
WO2023165528A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
CN120225518A (zh) * 2022-11-15 2025-06-27 伊莱利利公司 Ahr激动剂
CN119874716B (zh) * 2025-03-27 2025-07-15 上海隆盛化工有限公司 1-氯-6,8-二氟-7-异丙基苯并呋喃并[2,3-c]吡啶及其合成方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953457A (en) * 1972-07-28 1976-04-27 Eli Lilly And Company Agent for the control of plant-pathogenic organisms
US4252806A (en) * 1979-09-24 1981-02-24 Mead Johnson & Company Triazoloquinolones

Similar Documents

Publication Publication Date Title
JP2006520397A5 (enExample)
JP2005500311A5 (enExample)
JP2005539088A5 (enExample)
JP2005523922A5 (enExample)
JP2008510828A5 (enExample)
JP2009504591A5 (enExample)
JP2009529540A5 (enExample)
JP2003519676A5 (enExample)
JP2006522035A5 (enExample)
JP2008540554A5 (enExample)
JP2005523310A5 (enExample)
JP2004501940A5 (enExample)
JP2006505543A5 (enExample)
JP2005530811A5 (enExample)
JP2008540547A5 (enExample)
CA2615022A1 (en) Hcv ns3 protease inhibitors
JP2012508252A5 (enExample)
JP2020122016A5 (enExample)
JP2005289914A5 (enExample)
JP2005518357A5 (enExample)
JP2010535706A5 (enExample)
JP2005526773A5 (enExample)
JP2005521676A5 (enExample)
JP2003507380A5 (enExample)
JP2004535380A5 (enExample)